Back to companies

Coherus BioSciences Inc: Overview

Coherus BioSciences Inc (Coherus) is a biopharmaceutical company that conducts research, development and commercialization of immunotherapies to treat cancer. The company markets Udenyca (pegfilgrastim-cbqv), a biosimilar of Neulasta, and Cimerli (ranibizumab-eqrn), a biosimilar of Lucentis, in the US. Coherus products find its application for the treatment of various therapeutic areas which includes nasopharyngeal carcinoma, hepatocellular carcinoma, non-small lung cancer, small cell lung cancer and solid tumors. It is evaluating Toripalimab’s pivotal clinical trial for the treatment of nasopharyngeal carcinoma. The company also plans to launch Humira, a biosimilar Yusimry (adalimumab-aqvh) in the current fiscal year. It collaborates with other organizations to develop drug candidates. Coherus is headquartered in Redwood City, California, the US.

Gain a 360-degree view of Coherus BioSciences Inc and make more informed decisions for your business Gain a 360-degree view of Coherus BioSciences Inc and make more informed decisions for your business Contact Us
Headquarters United States of America

Address C/O Dennis M. Lanfear, 201 Redwood Shores Parkway, Suite 200, Redwood City, California, 94065


Telephone 1 650 6493530

No of Employees 306

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange CHRS (NASD)

Revenue (2022) $257.2M 21.9% (2022 vs 2021)

EPS XYZ

Net Income (2022) XYZ 18.5% (2022 vs 2021)

Market Cap* $271.6M

Net Profit Margin (2022) XYZ 33.1% (2022 vs 2021)

* As of and is in US$
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Contact Us

Coherus BioSciences Inc premium industry data and analytics

30+

Clinical Trials

Determine Coherus BioSciences Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

30+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Coherus BioSciences Inc’s relevant decision makers and contact details.

18+

Catalyst Calendar

Proactively evaluate Coherus BioSciences Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

17+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

13+

Pipeline Drugs

Identify which of Coherus BioSciences Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

6

Sales & Consensus Forecasts

Understand the current and future drug revenue for Coherus BioSciences Inc and assess market opportunity for new entrants with patient population 8-year forecasts.

3

Marketed Drugs

Understand Coherus BioSciences Inc’s commercialized product portfolio to stay one step ahead of the market.

1

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Coherus BioSciences Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Pipeline UDENYCA
Toripalimab: YUSIMRY
Nasopharyngeal Carcinoma CIMERLI
XYZ XYZ
XYZ XYZ
XYZ XYZ
Understand Coherus BioSciences Inc portfolio and identify potential areas for collaboration Understand Coherus BioSciences Inc portfolio and identify potential areas for collaboration Contact Us

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2024 Contracts/Agreements In February, the company and Pharmakon Advisors entered into an agreement to modify the terms of its loan agreement.
2024 New Products/Services In February, the company introduced UDENYCA ONBODY.
2024 Contracts/Agreements In January, the company entered into an agreement to sell CIMERLI (ranibizumab-eqrn) to Sandoz for US$170 million.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Contact Us
Image for loader

Competitor Comparison

Key Parameters Coherus BioSciences Inc F. Hoffmann-La Roche Ltd Merck & Co Inc Pfizer Inc AbbVie Inc
Headquarters United States of America Switzerland United States of America United States of America United States of America
City Redwood City Basel Kenilworth New York North Chicago
State/Province California - New Jersey New York Illinois
No. of Employees 306 103,605 72,000 88,000 50,000
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Contact Us
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Contact Us
Executives
Name Position Board Since Age
Dennis M. Lanfear Chairman; Chief Executive Officer; President Executive Board 2010 66
Rosh Dias, MD. Chief Medical Officer Senior Management 2022 -
Vladimir Vexler, Ph.D. Chief Scientific Officer Senior Management 2018 64
Rebecca Sunshine Chief Human Resources Officer Senior Management - -
Chris Slavinsky Chief Business and Legal Officer Senior Management 2022 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Coherus BioSciences Inc key executives to enhance your sales strategy Gain insight into Coherus BioSciences Inc key executives to enhance your sales strategy Contact Us
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward